Figure S1 from Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
التفاصيل البيبلوغرافية
العنوان:
Figure S1 from Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
American Association for Cancer Research (AACR), 2023.
سنة النشر:
2023
الوصف:
(A) FACS data for UACC-62 cell line following 200nM and 2000nM treatment with BVD-523 for 24 hours. (B) Percentage of MIAPaCa2 cells in G1, S, or G2 phase of the cell cycle following 0, 24 and 48 hours of 5μM BVD-523 treatment.